NFE2L2 and primary biliary cholangitis: There are numerous pharmaceutical and nutraceutical activators of Nrf2 with only a few approved as disease modifying treatment of MS: DMF [200,201], MMF and DRF; schistosomiasis: oltipraz; and primary biliary cirrhosis: ursodiol.